Our researchers are dedicated to creating change and work tirelessly to produce positive outcomes for patients. Some of our greatest impacts took decades to come to fruition, so we know good things take time. But we also know that if there is an opportunity to accelerate an outcome, we need to do all we can.

To achieve this, we launched a new initiative called Health Outcome Programs (HOPs) which aim to produce discrete and visible health outcomes. Sooner.

Our vision is to build an innovative and internationally recognised medical research enterprise that delivers improvements in clinical care.

What does this mean? It means we are backing up our words with actions. It means, progressing our research into improved health outcomes. And it means working closely with our hospital and health partners to help patients. 

The Health Outcome Program represents a fresh approach to Faculty research. These are very specific and targeted programs of research that address a single health problem and will become ‘flagship’ programs that we’re internationally renowned for.

For Researchers

If you are a Faculty of Medicine researcher and want to learn more about HOPs, please visit the Faculty Intranet.

Health Outcome Programs commencing in 2017:

Personalisation of antimicrobial therapy in critically ill patients: meeting a global challenge

Critically ill patients have high rates of infection and very poor outcomes that are often associated with sub-optimal use of antibiotic therapy. The team proposes to use technological advances incorporating whole genome sequencing to rapidly determine which bacteria is causing infection in critically ill patients and to which antibiotics they are sensitive. Knowledge of how sensitive the bacteria is to the most suitable antibiotic, can then be combined with knowledge of what antibiotic concentrations are likely to occur in the individual patient, to then inform the clinical team the exact drug and dose combination for optimal treatment of the patient. The research program will seek to establish this process and then test it in a clinical environment and quantify its value to the health system and individual patients.

The team comprises Professor Jason Roberts UQCCR, Professor David Paterson UQCCR, Professor Jeffrey Lipman UQCCR, Dr Patrick Harris UQCCR, A/Professor Scott Beatson SCMB and Professor Mark Schembri SCMB.

3D QMelanoma – Targeted early detection of melanoma utilising a 3D teledermatology (3DT) network

Melanoma incidence continues to increase in Australia, with Queensland labelled as ‘melanoma capital of the world’. Early melanoma diagnosis is crucial to improve prognosis and patient outcomes. This research program focuses on innovative solutions to address the problem of high melanoma incidence and mortality. While general population screening for melanoma is not recommended, there is strong support for targeted screening of people at high risk.

The primary aim of the 3D QMelanoma project is to improve early detection of melanoma in high risk Queenslanders. The team has access to the largest skin cancer study in Australia, QSkin, and will recruit high risk participants to conduct a nested feasibility study of an innovative targeted screening program incorporating 3D total body photography.  This world-first targeted screening program will assess clinical outcomes, health service outcomes and consumer behaviour outcomes.

The team comprises Professor H. Peter Soyer UQDI, Professor David Whiteman QIMR Berghofer Medical Research Institute, Professor Luke Connelly UQ Centre for Business and Economics of Health, Professor Mieke van Driel UQ Discipline of General Practice, Dr Anna Finnane UQ Dermatology Research Centre, Professor Len Gray UQ Centre for Health Services Research, Professor Monika Janda QUT, A/Professor Stuart Macgregor QIMR, Dr Erin McMeniman, UQ Faculty of Medicine, Professor Mark Smithers, UQ Discipline of Surgery.

This project will also run in collaboration with The Australian Skin and Skin Cancer Centre.